Neurodegenerative Disease

DMARDs for rheumatoid arthritis linked to lower dementia risk

April 12, 2024 - Research published in Rheumatic & Musculoskeletal Disease found that patients with rheumatoid arthritis (RA) who were taking biological disease-modifying antirheumatic drugs (DMARDs) had a 24% lower risk of dementia. Previous studies have linked RA with an elevated risk of dementia, identifying chronic systemic inflammation and dysregulation of...

Read More


More Articles

FDA Clears IND for New Parkinson’s Disease Treatment Using IPSCs

by Veronica Salib

Today, Aspen Neuroscience announced that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a new Parkinson’s Disease gene...

Exploring FDA-Approved Drugs and Potential Treatment Options for ALS

by Alivia Kaylor

According to 2017 CDC data, over 31,000 people are living with amyotrophic lateral sclerosis (ALS) in the United States. In America, approximately 5,000 individuals are diagnosed with ALS annually. ALS is associated with high costs, as the...

Sleeping Pills Linked to Lower Levels of Alzheimer’s Disease Proteins

by Veronica Salib

A recent study published in the Annals of Neurology identified a link between sleeping pill use and lowered levels of Alzheimer's disease protein. Protein buildups and plaques identified in...

FDA Accelerates Approval of a New Alzheimer’s Disease Drug, Leqembi

by Veronica Salib

Based on the results of a double-blind, placebo-controlled, the FDA granted the accelerated approval of Leqembi for Alzheimer’s disease, making it the second approved medication targeting the...

Initiating Dementia Treatment, Pharmacological Interventions

by Veronica Salib

The WHO notes that approximately 55 million people in the world have dementia. Considering the rate of aging and the complications that coincide with aging, Alzheimer's Disease International anticipates that the number of people with...

FDA Clears Clinical Trials on Investigational New Drug for ALS

by Veronica Salib

Amyotrophic lateral sclerosis, ALS, is a life-threatening neurodegenerative disease that can lead to paralysis and death. Over 5,000 individuals in the United States are diagnosed with ALS each year,...

US Department of Defense Grants $2.97 Million to Treventis

by Veronica Salib

According to a press statement released on October 18, 2022, the Treventis Corporation, a biotechnology company, was granted $2.97 million to research and develop an anti-tau misfolding drug. The press...

FDA Awards 19 Grants for Rare Disease Research

by Veronica Salib

On October 17, 2022, the FDA announced that its Orphan Products Grants Program has awarded 19 grants and 2 contracts, amounting to over $38 million, for rare disease research. This action will...

Diversifying Clinical Trials through Telehealth Platforms

by Veronica Salib

In a recent press release, Ro — a healthcare company — announced that it will partner with the National Institute of Aging, a subset of the NIH, to use its telehealth platform to diversify...

Combining Existing Drugs Introduced New Parkinson’s Disease Treatment

by Veronica Salib

The National Institute of Neurological Disorders and Stroke, a subset of the NIH, estimates that nearly one million people in the United States have Parkinson’s disease. Considering the ever-aging population and the increased risk of...

FDA and NIH Launch Partnership for Rare Neurodegenerative Diseases

by Veronica Salib

Earlier this week, the FDA and NIH announced their launch of a public–private partnership for research on rare neurodegenerative diseases. The partnership, called the Critical Path for Rare...

Recent Articles